496 related articles for article (PubMed ID: 27242953)
41. Endogenous lectins shape the function of dendritic cells and tailor adaptive immunity: mechanisms and biomedical applications.
Mascanfroni ID; Cerliani JP; Dergan-Dylon S; Croci DO; Ilarregui JM; Rabinovich GA
Int Immunopharmacol; 2011 Jul; 11(7):833-41. PubMed ID: 21296197
[TBL] [Abstract][Full Text] [Related]
42. Functions of galectins as 'self/non-self'-recognition and effector factors.
Vasta GR; Feng C; González-Montalbán N; Mancini J; Yang L; Abernathy K; Frost G; Palm C
Pathog Dis; 2017 Jul; 75(5):. PubMed ID: 28449072
[TBL] [Abstract][Full Text] [Related]
43. Dissecting the pathophysiologic role of endogenous lectins: glycan-binding proteins with cytokine-like activity?
Toscano MA; Ilarregui JM; Bianco GA; Campagna L; Croci DO; Salatino M; Rabinovich GA
Cytokine Growth Factor Rev; 2007; 18(1-2):57-71. PubMed ID: 17321195
[TBL] [Abstract][Full Text] [Related]
44. Bacterial glycans and their interactions with lectins in the innate immune system.
Prado Acosta M; Lepenies B
Biochem Soc Trans; 2019 Dec; 47(6):1569-1579. PubMed ID: 31724699
[TBL] [Abstract][Full Text] [Related]
45. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation.
Rabinovich GA; Toscano MA
Nat Rev Immunol; 2009 May; 9(5):338-52. PubMed ID: 19365409
[TBL] [Abstract][Full Text] [Related]
46. Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways.
Rabinovich GA; Conejo-García JR
J Mol Biol; 2016 Aug; 428(16):3266-3281. PubMed ID: 27038510
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.
Angata T; Nycholat CM; Macauley MS
Trends Pharmacol Sci; 2015 Oct; 36(10):645-660. PubMed ID: 26435210
[TBL] [Abstract][Full Text] [Related]
48. Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy.
Makandar AI; Jain M; Yuba E; Sethi G; Gupta RK
Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560459
[TBL] [Abstract][Full Text] [Related]
49. Targeting C-type lectin receptors with multivalent carbohydrate ligands.
Lepenies B; Lee J; Sonkaria S
Adv Drug Deliv Rev; 2013 Aug; 65(9):1271-81. PubMed ID: 23727341
[TBL] [Abstract][Full Text] [Related]
50. Siglecs, sialic acids and innate immunity.
Crocker PR; Varki A
Trends Immunol; 2001 Jun; 22(6):337-42. PubMed ID: 11377294
[TBL] [Abstract][Full Text] [Related]
51. Glycans and Glycan-Binding Proteins in Atherosclerosis.
Eckardt V; Weber C; von Hundelshausen P
Thromb Haemost; 2019 Aug; 119(8):1265-1273. PubMed ID: 31266083
[TBL] [Abstract][Full Text] [Related]
52. Role of galectins in lung cancer.
Chang WA; Tsai MJ; Kuo PL; Hung JY
Oncol Lett; 2017 Nov; 14(5):5077-5084. PubMed ID: 29113148
[TBL] [Abstract][Full Text] [Related]
53. Siglecs family used by pathogens for immune escape may engaged in immune tolerance in pregnancy.
Chen Y; Chen H; Zheng Q
J Reprod Immunol; 2023 Sep; 159():104127. PubMed ID: 37572430
[TBL] [Abstract][Full Text] [Related]
54. Galectins as self/non-self recognition receptors in innate and adaptive immunity: an unresolved paradox.
Vasta GR; Ahmed H; Nita-Lazar M; Banerjee A; Pasek M; Shridhar S; Guha P; Fernández-Robledo JA
Front Immunol; 2012; 3():199. PubMed ID: 22811679
[TBL] [Abstract][Full Text] [Related]
55. Siglecs and their roles in the immune system.
Crocker PR; Paulson JC; Varki A
Nat Rev Immunol; 2007 Apr; 7(4):255-66. PubMed ID: 17380156
[TBL] [Abstract][Full Text] [Related]
56. Aberrant Sialylation in Cancer: Therapeutic Opportunities.
Munkley J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077781
[TBL] [Abstract][Full Text] [Related]
57. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily.
Kelm S; Pelz A; Schauer R; Filbin MT; Tang S; de Bellard ME; Schnaar RL; Mahoney JA; Hartnell A; Bradfield P
Curr Biol; 1994 Nov; 4(11):965-72. PubMed ID: 7533044
[TBL] [Abstract][Full Text] [Related]
58. Glycans as a key factor in self and nonself discrimination: impact on the breach of immune tolerance.
Alves I; Fernandes Â; Santos-Pereira B; Azevedo CM; Pinho SS
FEBS Lett; 2022 Jun; 596(12):1485-1502. PubMed ID: 35383918
[TBL] [Abstract][Full Text] [Related]
59. Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy.
Rodrigues Mantuano N; Natoli M; Zippelius A; Läubli H
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020245
[TBL] [Abstract][Full Text] [Related]
60. Multivalent ligands for siglecs.
O'Reilly MK; Paulson JC
Methods Enzymol; 2010; 478():343-63. PubMed ID: 20816489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
